March 9, 2022

By Doris Yu

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.

欲了解更多，请浏览以下网址：

https://www.bioworld.com/articles/516796-inxmed-raises-50m-to-develop-cancer-therapy-in-the-us-china